

Research article

Open Access

## Mechanism of PP2A-mediated IKK $\beta$ dephosphorylation: a systems biological approach

Johannes Witt\*<sup>†1</sup>, Sandra Barisic<sup>†2</sup>, Eva Schumann<sup>2</sup>, Frank Allgöwer<sup>3</sup>, Oliver Sawodny<sup>1</sup>, Thomas Sauter<sup>1,4</sup> and Dagmar Kulms\*<sup>2</sup>

Address: <sup>1</sup>Institute for System Dynamics, Universität Stuttgart, Pfaffenwaldring 9, 70569 Stuttgart, Germany, <sup>2</sup>Institute of Cell Biology and Immunology, Universität Stuttgart, Allmandring 31, 70569 Stuttgart, Germany, <sup>3</sup>Institute for Systems Theory and Automatic Control, Universität Stuttgart, Pfaffenwaldring 9, 70569 Stuttgart, Germany and <sup>4</sup>Life Sciences Research Unit, University of Luxembourg, 162 A, avenue de la Faïencerie, 1511 Luxembourg, Luxembourg

Email: Johannes Witt\* - witt@isys.uni-stuttgart.de; Sandra Barisic - sandra.barisic@izi.uni-stuttgart.de;

Eva Schumann - eva.schumann@webpear.de; Frank Allgöwer - allgower@ist.uni-stuttgart.de; Oliver Sawodny - sawodny@isys.uni-stuttgart.de; Thomas Sauter - thomas.sauter@uni.lu; Dagmar Kulms\* - dagmar.kulms@izi.uni-stuttgart.de

\* Corresponding authors †Equal contributors

Published: 16 July 2009

Received: 19 March 2009

BMC Systems Biology 2009, 3:71 doi:10.1186/1752-0509-3-71

Accepted: 16 July 2009

This article is available from: <http://www.biomedcentral.com/1752-0509/3/71>

© 2009 Witt et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Biological effects of nuclear factor- $\kappa$ B (NF $\kappa$ B) can differ tremendously depending on the cellular context. For example, NF $\kappa$ B induced by interleukin-1 (IL-1) is converted from an inhibitor of death receptor induced apoptosis into a promoter of ultraviolet-B radiation (UVB)-induced apoptosis. This conversion requires prolonged NF $\kappa$ B activation and is facilitated by IL-1 + UVB-induced abrogation of the negative feedback loop for NF $\kappa$ B, involving a lack of inhibitor of  $\kappa$ B (I $\kappa$ B $\alpha$ ) protein reappearance. Permanent activation of the upstream kinase IKK $\beta$  results from UVB-induced inhibition of the catalytic subunit of Ser-Thr phosphatase PP2A (PP2Ac), leading to immediate phosphorylation and degradation of newly synthesized I $\kappa$ B $\alpha$ .

**Results:** To investigate the mechanism underlying the general PP2A-mediated tuning of IKK $\beta$  phosphorylation upon IL-1 stimulation, we have developed a strictly reduced mathematical model based on ordinary differential equations which includes the essential processes concerning the IL-1 receptor, IKK $\beta$  and PP2A. Combining experimental and modelling approaches we demonstrate that constitutively active, but not post-stimulation activated PP2A, tunes out IKK $\beta$  phosphorylation thus allowing for I $\kappa$ B $\alpha$  resynthesis in response to IL-1. Identifiability analysis and determination of confidence intervals reveal that the model allows reliable predictions regarding the dynamics of PP2A deactivation and IKK $\beta$  phosphorylation. Additionally, scenario analysis is used to scrutinize several hypotheses regarding the mode of UVB-induced PP2Ac inhibition. The model suggests that down regulation of PP2Ac activity, which results in prevention of I $\kappa$ B $\alpha$  reappearance, is not a direct UVB action but requires instrumentality.

**Conclusion:** The model developed here can be used as a reliable building block of larger NF $\kappa$ B models and offers comprehensive simplification potential for future modeling of NF $\kappa$ B signaling. It gives more insight into the newly discovered mechanisms for IKK deactivation and allows for substantiated predictions and investigation of different hypotheses. The evidence of constitutive activity of PP2Ac at the IKK complex provides new insights into the feedback regulation of NF $\kappa$ B, which is crucial for the development of new anti-cancer strategies.

## Background

Nuclear factor  $\kappa$ B (NF $\kappa$ B) (p65/p50) is a transcription factor of central importance in inflammation and anti-apoptotic signaling [1]. Since constitutive activation of NF $\kappa$ B was shown to contribute to the maintenance of a range of cancers by inducing expression of anti-apoptotic genes [2-4], manifold approaches were made to develop new anti-cancer strategies based on NF $\kappa$ B inhibition [3,5]. Canonical activation of NF $\kappa$ B by the pro-inflammatory cytokine interleukin-1 (IL-1) requires activation of the inhibitor of  $\kappa$ B (I $\kappa$ B $\alpha$ ) kinase complex (IKK), especially phosphorylation of the catalytic subunit IKK $\beta$  at Ser 177/181 [6]. Phosphorylated IKK $\beta$  consequently phosphorylates I $\kappa$ B $\alpha$  at Ser 32/36, leading to its poly-ubiquitination and proteasomal degradation. Liberated NF $\kappa$ B translocates into the nucleus to activate transcription of responsive genes [6]. Accordingly, co-stimulation of cells with IL-1 was shown to inhibit death ligand-induced apoptosis via up-regulation of anti-apoptotic genes and their products [7,8]. In contrast, ultraviolet-B radiation (UVB)-induced apoptosis was not inhibited but significantly enhanced upon co-stimulation with IL-1. This process on the one hand was associated with NF $\kappa$ B-dependent repression of anti-apoptotic genes. On the other hand, it coincided with long term transcriptional up-regulation followed by pronounced release of tumor necrosis factor  $\alpha$  (TNF $\alpha$ ), which activates the death receptor TNF-R1 in an autocrine fashion, thereby enhancing UVB-induced apoptosis [9]. Both effects were shown to be NF $\kappa$ B dependent, indicating that UVB is capable to persistently convert NF $\kappa$ B function from an inhibitor into a promoter of apoptosis. This newly-discovered UVB-mediated pro-apoptotic activity of NF $\kappa$ B appears of utmost importance, because it challenges the dogma of NF $\kappa$ B inhibition as a general approach to fight cancer. In contrast, the new evidence provides a basis for alternative approaches in cancer therapy combining induction of DNA damage with NF $\kappa$ B activation rather than inhibition. It is therefore of prime interest to unravel the detailed mechanisms underlying this complex feedback regulation of the NF $\kappa$ B system.

In order to fully convert the cellular NF $\kappa$ B response from anti- to pro-apoptotic functions, transient NF $\kappa$ B activation appears to be insufficient. In fact, recent data revealed a prolonged IL-1-induced nuclear activity of NF $\kappa$ B in epithelial cells co-treated with UVB to be responsible for switching the cellular response towards a pro-apoptotic phenotype [10]. It is generally accepted that activation of NF $\kappa$ B triggers transcription of I $\kappa$ B $\alpha$ , thereby inducing resynthesis of its inhibitor in a negative regulatory feedback loop [11]. This negative feedback loop was shown to be completely abrogated in cells co-treated with IL-1 and UVB, caused by immediate phosphorylation and proteasomal degradation of the newly synthesized protein [10]. Instant phosphorylation of resynthesized I $\kappa$ B $\alpha$  was facili-

tated by continuously activated IKK $\beta$ . Chronic Ser 177/181 phosphorylation of IKK $\beta$  was due to UVB-induced inhibition of the catalytic subunit of the Ser-Thr phosphatase PP2A (PP2Ac) [10]. As a consequence, active NF $\kappa$ B persists in the nucleus for several hours providing sufficient time to fundamentally change the transcriptional program and physiologic response of the cell.

The exact molecular mechanisms and kinetics, however, underlying PP2A-mediated IKK $\beta$  dephosphorylation in response to IL-1 as well as UVB-induced PP2A inhibition remain to be determined. Either constitutively active or signal activated PP2A may modulate IKK $\beta$  activity. To identify the responsible mode of action we developed a mathematical model of IKK $\beta$  phosphorylation based on experimental data.

Several models describing NF $\kappa$ B activation following IKK phosphorylation have been published to date [12], most of them based on the seminal model of Hoffmann et al. [13]. Since these models mainly focus on I $\kappa$ B/NF $\kappa$ B kinetics, they often do not explicitly describe receptor kinetics. A problem of these generally large models, which is often exacerbated by a comparatively sparse experimental data basis, is that parameters are frequently functionally related and can therefore not be determined unambiguously: the parameters are not identifiable [14]. Particularly, the amount of additional parameters and the system complexity increase tremendously when the I $\kappa$ B/NF $\kappa$ B part of the model influences IKK or when the signaling cascade is extensively modeled. For example, studies of Cho et al. [15] and Park et al. [16] presented very detailed models of TNF-mediated signaling upstream of I $\kappa$ B $\alpha$ , including receptor kinetics and IKK activation. While this approach is very valuable for theoretical studies, the estimation of reliable parameter values would require a huge amount of experimental data. Consequently, Werner et al. [17] did not fit their model to IKK activity data but rather used these data as an input for the I $\kappa$ B/NF $\kappa$ B module. Cheong et al. [18] assessed the problem in a more mathematical way and modeled IKK kinetics by activation and deactivation functions without direct biological counterpart. Those approaches avoid most identifiability problems, but do not provide an insight into the activation and deactivation processes of IKK. A model for IL-1 receptor signaling exemplifying the identifiability issue has been proposed recently, but lacks experimental validation [19]. In sum, existing models contribute to a deeper understanding of the phosphorylation dynamics of IKK $\beta$ , but an experimentally validated model for IL-1 signaling with fully identifiable parameters including the essential biological processes has not been devised to date.

Focusing on IKK $\beta$  phosphorylation following IL-1 stimulation, we present a model with pronounced modularity

to warrant reusability of either the entire model or some parts of it. The individual modules are not connected by mass flows, but by unidirectional signal flows, and can therefore also be considered decoupled from the remaining model. Particular attention is paid to a careful simplification resulting in a very good identifiability of the parameters. We use a combination of modeling and experimental methods to analyze the system behavior, and provide evidence that constitutively active PP2A continuously dephosphorylates IKK $\beta$ , thereby sustaining the negative feedback loop for NF $\kappa$ B and maintaining proper cellular function.

**Results**


**UVB inhibits I $\kappa$ B $\alpha$  reappearance via continuous phosphorylation of IKK $\beta$**

Initiation of transient NF $\kappa$ B activation upon IL-1 stimulation (10 ng/ml) requires Ser177/181 phosphorylation of IKK $\beta$ . Subsequent I $\kappa$ B $\alpha$  phosphorylation and proteasomal degradation is completed at the latest after 15 min. Reappearance of I $\kappa$ B $\alpha$  after 90 min perfectly matches dephosphorylation of IKK $\beta$  and disappearance of NF $\kappa$ B from the nucleus (Figure 1). Costimulation with UVB, however, results in complete inhibition of I $\kappa$ B $\alpha$  reappearance


and NF $\kappa$ B termination. Under these conditions the phosphorylation status of IKK $\beta$  is somewhat lowered after 90 min but still remains at elevated levels over hours, ensuring continuous phosphorylation and degradation of gradually upcoming levels of resynthesized I $\kappa$ B $\alpha$  (Figure 1).

**The activation status of PP2A at the IKK complex**

PP2A is a ubiquitously expressed Ser/Thr phosphatase which is involved in a wide range of cellular processes, only a very small fraction being responsible for IKK $\beta$  regulation, meaning that overall measured PP2A activity may differ from the specific local activation status. In general, two mechanisms of PP2A activity may explain the observed phosphorylation status of IKK $\beta$  (Figure 2A). Either inactive PP2A is recruited to the IKK complex in unstimulated cells and becomes activated with a certain delay following IL-1 treatment. Activated PP2A then terminates IKK $\beta$  activity, thereby allowing for stabilization of resynthesized I $\kappa$ B $\alpha$ . Alternatively, a constitutively low level of activated PP2A continuously counteracts the IKK $\beta$  phosphorylation and thus activity state (Figure 2A). Previous data from our lab revealed PP2Ac to be constitutively recruited to IKK $\beta$ , even in unstimulated cells [10]. Here,



**Figure 1**  
**Failure of I $\kappa$ B $\alpha$  reappearance coincides with continuous IKK $\beta$  phosphorylation and NF $\kappa$ B activation.** KB cells were left untreated or stimulated with 10 ng/ml IL-1 alone or in combination with UVB (300 J/m<sup>2</sup>). At the indicated time points cytosolic as well as nuclear protein extracts were generated. Cytosolic extracts were analysed for the phosphorylation status of IKK $\beta$  and I $\kappa$ B $\alpha$  degradation by Western-blotting. Equal loading was monitored with an antibody against  $\alpha$ -tubulin. In parallel, nuclear translocation of NF $\kappa$ B was determined by EMSA with an NF $\kappa$ B specific oligonucleotide. Data shown represent one out of three independently performed experiments.




**Figure 2**  
**Hypotheses of PP2A activity.** (A) The IKK phosphorylation curve consists of two phases. Phase I is defined by an increase of phosphorylated IKK, indicating a predominant kinase activity. Phosphorylated IKK decreases in phase II, indicating a predominant phosphatase activity. Both activation of PP2A by IL-1 and constitutive PP2A activity could explain this behaviour. Scaling is different for PP2A and the IKK kinase. (B) Cells were left untreated or were stimulated with IL-1 for 15 min and 2 h respectively. Subsequently, PP2Ac was immunoprecipitated and subjected to an *in vitro* phosphatase assay using a threonine-phosphopeptide as a substrate. Pooled data of three independently performed experiments are depicted. (C) Cells were pre-stimulated or not with 20 μM MG132 for 1 h. Subsequently cells were left untreated or stimulated with IL-1 for 15 min or 2 h. Phosphorylation status of IKKβ and protein status of IκBα were determined by Western-blot analysis using α-tubulin as loading control.

the total cellular PP2Ac activity was determined after 15 min of IL-1 treatment, reflecting initial IκBα degradation, and after 2 h, representing the time point of full IκBα resynthesis (see Figure 1). Phosphatase activity assay did not reveal any significant changes in overall cellular PP2Ac activity at the different time points measured (Figure 2B), allowing to assume that PP2A located at the IKK complex might also be constitutively active. In order to investigate whether this assumption is consistent with the observed IKKβ phosphorylation pattern and because PP2Ac amounts recruited to IKK are too small to be reliably analyzed separately, we designed an ordinary differential equation model resuming the essential processes based on the assumption of constitutive PP2A activity.

However, to rule out that PP2A may additionally target IκBα directly for dephosphorylation, phosphorylated IκBα was captured by addition of the proteasome inhibitor MG132. 15 min after IL-1 stimulation, IKK is strongly phosphorylated and IκBα disappeared due to proteasomal degradation. Addition of MG132 consequently resulted in appearance of non-degradable, phosphorylated IκBα, evident from the shifted IκBα band (Figure 2C). Two hours later, IKKβ was completely dephosphorylated and IκBα reappeared as described before. Upon proteasome inhibition IκBα stayed phosphorylated over the observed time period, indicating that PP2A primarily targeted IKKβ and not IκBα, the latter, if at all, with a significantly slower kinetics (Figure 2C).

**IKK phosphorylation following IL-1 stimulation can be modeled decoupled from the downstream processes**

Our model is based on the following biochemical reactions:



where ILRc and ILR represent the IL-1 receptor with and without bound IL-1, respectively, IKKp and IKK denote

phosphorylated and unphosphorylated IKKβ, respectively, and PP2A reflects active PP2Ac at the IKK complex. The model structure is shown in Figure 3A. The significance of the model parameters is depicted in Table 1.

These reactions imply that IKK phosphorylation can be considered independently of the downstream processes. In contrast, the vast majority of mathematical models for NFκB signaling pathways are based on the one by Hoffmann et al. [13], representing phosphorylation of IκBα as transient complexing of phosphorylated IKK with IκBα, where only uncomplexed IKK can be deactivated. In these models, IKK phosphorylation kinetics can therefore not be considered independently of the IκBα/NFκB kinetics. However, complexing of IKK with IκBα can also be approximated as a catalytic influence of IKK on IκBα, using the quasi-steady-state approximation [20] for all complexes involving IKK. Considering the model by Lipniacki et al. [21], it can be shown that the behavior of the reduced model is almost identical to the kinetics of the original one (Additional file 1, I). This finding offers a significant simplification potential for future modeling of NFκB signaling. Since the further coupling of IKKβ and NFκB via the A20 feedback only exists for TNFα induced NFκB signaling [22], but has been shown to be negligible for IL-1 induced NFκB signaling [23], we can consider IKKβ kinetics independently of the downstream processes involving NFκB.


Assuming mass action kinetics, an initially completely uncomplexed receptor, initially unphosphorylated IKK and constitutively active PP2A, the system can now be written in terms of differential equations as follows:

$$\begin{aligned}
 \frac{d \text{ILR}(t)}{dt} &= -\text{ka} \cdot \text{il}(t) \cdot \text{ILR}(t), \text{ILR}(0) = 1 \\
 \frac{d \text{ILRc}(t)}{dt} &= \text{ka} \cdot \text{il}(t) \cdot \text{ILR}(t) - \text{ki} \cdot \text{ILRc}(t), \text{ILRc}(0) = 0 \\
 \frac{d \text{IKKp}(t)}{dt} &= \text{kp} \cdot \text{ILRc}(t) \cdot \text{IKK}(t) - \text{kdp} \cdot \text{PP2A}(t) \cdot \text{IKKp}(t), \text{IKKp}(0) = 0 \\
 \frac{d \text{PP2A}(t)}{dt} &= -\text{kuv} \cdot \text{uv}(t) \cdot \text{PP2A}(t), \text{PP2A}(0) = 1 \\
 \text{with IKK}(t) &= 1 - \text{IKKp}(t).
 \end{aligned}$$

**Table 1: Model parameters in the reference scenario**

Variable	Process	Value	Unit
ka	association of IL-1 to the receptor	6.7	(μM·s) <sup>-1</sup>
ki	internalization of the receptor complex	0.0034	s <sup>-1</sup>
kp	phosphorylation of IKK	0.095	s <sup>-1</sup>
kdp	dephosphorylation of IKKp	0.00076	s <sup>-1</sup>
kuv	deactivation of PP2A under UVB	0.00024	s <sup>-1</sup>
IKKscale	scaling of the model to the data	0.96	-

Note that the unit μM occurs only in the reaction involving IL-1, since all state variables are dimensionless and can be interpreted as fraction of the total initial protein.



**Figure 3**  
**Schematic representation and simulation results of the mathematical model of the activation status of PP2Ac at the IKK complex.** (A) The IL-1 receptor and IL-1 form the IL-1 receptor complex which triggers IKK $\beta$  phosphorylation. PP2Ac dephosphorylates phosphorylated IKK $\beta$  and is deactivated by UVB radiation. Ellipses denote model inputs, boxes with solid lines denote state variables, and boxes with dotted lines denote species whose concentration can be calculated from the state variables by mass conservation relations. Normal arrows denote mass flows following mass action kinetics, circles at the arrow tail signify that the involved species participates catalytically in the reaction (signal flow). (B) The model assuming constitutive PP2Ac activity matches the experimental data calculated from Figure 1 well ( $\chi^2 = 10.46 + 13.99 = 24.45$ ). Experimental data are shown as mean and standard deviation of three independently performed experiments.

The inputs  $il(t)$  and  $uv(t)$  are step functions:  $il(t)$  is 0  $\mu\text{M}$  for  $t < 0$ , and 0.000588  $\mu\text{M}$  for  $t \geq 0$ , corresponding to the experimentally applied dose of 10 ng/ml. With 300 J/m<sup>2</sup> UVB stimulation,  $uv(t)$  is the Heaviside function,  $uv(t) = 0$  for  $t < 0$ , and  $uv(t) = 1$  for  $t \geq 0$ . Consequently, without UVB stimulation  $uv(t) \equiv 0$ . The model was scaled to the experimental data using a unique scaling factor for all IKK observations. An upper bound of 0.095 s<sup>-1</sup> was imposed on  $kp$ , based on biophysical considerations (see Addi-

tional file 1, II). No bounds were assumed for the remaining parameters.

**The hypothesis of constitutive PP2A activity is consistent with the experimental data**

The model assuming constitutive PP2A activity (Figure 3A) was fitted to the experimentally determined IKK $\beta$  phosphorylation pattern following stimulation with IL-1 (10 ng/ml), with or without UVB co-stimulation. The sim-

ulation results match the experimental data remarkably well ( $\chi^2 = 10.46 + 13.99 = 24.45$ ; Figure 3B and Table 1), particularly when considering the relatively small system order. In the following, this model structure with these parameters is referred to as the reference scenario. Compared to experimental data, peak concentrations are reached much more rapidly in the simulation than in the experimental data. This effect can be attributed to the choice of the objective function rather than to limitations induced by the model structure: since the standard deviations are higher during the first 30 minutes, higher deviations are tolerated in this time interval. Indeed, a visually more satisfactory fit with peak concentrations shortly after 15 minutes is possible with a slightly larger  $\chi^2$  value (28.09, see Additional file 2) and very similar values for  $ka$ ,  $ki$ ,  $kuv$  and  $kdp$ . Results presented show that constitutive PP2A activity is indeed consistent with the observed IKK $\beta$  phosphorylation pattern.

A similar model developed for investigating the alternative hypothesis of initially inactive PP2Ac, however, yielded comparable results (see Additional file 3), so that none of the two possible mechanisms can be excluded based on modeling results. Consequently, experimental data are consistent with the principle of either hypothesis.

#### **Experimental data substantiate the constitutive activity of PP2A**

To finally address the activation status of PP2Ac and its impact on initial IKK $\beta$  phosphorylation we performed PP2Ac knock-down experiments. As a prerequisite, a sensitive IL-1 dose had to be determined allowing observation of minor changes in I $\kappa$ B $\alpha$  levels and IKK $\beta$  phosphorylation. Performing dose-response experiments ranging from 10 ng/ml to 0.1 ng/ml IL-1 for 15 min revealed 0.5 ng/ml to be the sensitive dose of choice upon which initial I $\kappa$ B $\alpha$  degradation has only partially taken place (Figure 4A). Using this sensitive dose of 0.5 ng/ml IL-1, delayed IKK $\beta$  phosphorylation was observed compared to treatment with 10 ng/ml (compare Figure 1 and Figure 4B). Investigating very short sampling intervals finally disclosed IKK $\beta$  phosphorylation to start very early 1 min after IL-1 treatment (Figure 4B and 4C). However, when PP2Ac was knocked down by siRNA, very early phosphorylation of IKK $\beta$  was enhanced, being most pronounced after 30 min of treatment (Figure 4C; for one representative Western Blot see Additional file 4). These data clearly indicate PP2A to be constitutively active when located at the IKK complex. Furthermore, the model demonstrates that no additional mechanism is required to explain the experimental data.

#### **The model parameters are very well identifiable**

In order to determine whether the estimated parameter values are unique, we conducted an identifiability analy-

sis as described in the *Methods* section. The  $\chi^2$  value of the best 10% of the fits was consistently 24.45. The distribution of the parameter values clearly shows that the parameters can be uniquely determined for the given observations within the very large investigated parameter range, as the variance in the parameter sets yielding the best  $\chi^2$  values is extremely low (Figure 5A). The parameter  $kp$  thereby attains its upper bound, so that the upper bound estimate affects the parameter identification. However, all parameters except  $kp$  itself are robust against variations of the upper bound in a range of at least two orders of magnitude (see Additional file 1).


When considering the influence of noise in the experimental data, the parameter values still remain meaningful: the lower and upper bounds of the 95% confidence intervals do not vary by more than a factor of 2 for any of the parameters (Table 2). Consequently, the determined parameter values allow for some predictions concerning the occurring processes: Firstly, the model parameters suggest that internalization of the receptor complex occurs within a few minutes. Furthermore, a fast association of IL-1 to the receptor is predicted, which is confirmed by literature data [24] (see also Additional file 1, III).

#### **The model rejects the hypothesis of immediate complete PP2A deactivation**

Finally, the model also makes predictions about the mode of PP2A deactivation. Direct deactivation of PP2Ac by UVB radiation (e.g. by destroying the active centre) would be expected to occur almost immediately. Since a relatively slow decrease of PP2A activity ( $t_{1/2} = \ln 2/kuv = 48$  min) is predicted, the model suggests an indirect and gradual effect of UVB on PP2Ac. In order to exclude the possibility of an immediate deactivation of PP2Ac in the model, we tested the special case  $kuv \rightarrow \infty$  (or equivalently  $kdp = 0$  for UVB radiation). The resulting fits clearly show that the model cannot match the experimental data if we assume immediate PP2A deactivation (Figure 5B). This indicates that UVB-induced gradual PP2Ac inactivation is an indirect effect that requires instrumentality by other molecules.

#### **IL-1 receptor internalization is fast and unaffected by UVB radiation**

IL-1-induced NF $\kappa$ B activation is terminated by IL-1 receptor (IL-1R) internalization, thereby limiting the duration of the exogenous input [25]. Although our data strongly indicate PP2Ac to be constitutively active at the IKK complex regulating the phospho-IKK $\beta$  turn over, prolonged IL-1 receptor (IL-1R) activation by UVB may alternatively influence the phospho-IKK status. To investigate whether UVB interferes with the kinetics of IL-1R internalization, and to validate the model prediction of fast internalization, FACS analysis was performed. Comparing cells



**Figure 4**  
**A sensitive IL-1 dose reveals PP2Ac to be constitutively active at the IKK complex.** (A) Cells were left untreated or stimulated with decreasing doses of IL-1 for 15 min as indicated. The status of the initial IκBα degradation was determined by Western-blot analysis. (B) Cells were left untreated or stimulated with a sensitive dose of 0.5 ng/ml as derived from (A) for the indicated time points. Initial phosphorylation status of IKKβ as well as degradation of IκBα was documented by Western-blot analysis. (C) Cells were transfected with scrambled siRNA or siRNA specifically knocking down PP2Ac. 48 h later, cells were stimulated with 0.5 ng/ml IL-1 for the indicated time points, and phosphorylation status of IKKβ, degradation of IκBα and protein level of PP2Ac were analysed by Western-blot. In each analysis α-tubulin served as loading control. IKKβ phosphorylation was quantified using Image Quant software. Pooled data of three independently performed experiments are summarised. One representative Western-blot analysis is shown as Additional file 4.

treated with IL-1 and IL-1 + UVB, respectively, revealed IL-1R internalization to follow almost identical kinetics, starting very early after 5 min and being completed latest after 60 min (Figure 6A), indicating changes of IL-1R internalization to be irresponsible for prolonged IKKβ phosphorylation. Since the high standard deviation between the independently performed experiments did not allow for a definitive rejection of the hypothesis, we additionally used the model to scrutinize this hypothesis: We altered the model by assuming that UVB radiation

does not affect IKKβ dephosphorylation, but alters the internalization of IL-1R (for model equations see Additional file 1, IV). The resulting fits (Figure 6B) are considerably worse ( $\chi^2 = 24.77 + 25.35 = 50.12$ ) than those of the original model, so that the model suggests rejection of this hypothesis.


The experiment also allows validation of the prediction of fast receptor internalization. The model predicts a receptor complex internalization half-life of  $\ln 2/k_i = 3.4$  min and a very rapid decrease of the total non-internalized receptor (Additional file 5). This nicely corresponds to the experimental observation that more than half of the receptor is internalized after 5 min (Figure 6A) and thus presents another indication for the validity of the model.

## Discussion

Tight regulation of NFκB by the negative feedback loop involving post-degradational resynthesis of IκBα is mandatory to ensure proper cellular function. Constitutive NFκB activation is linked to transformation, proliferation, suppression of apoptosis, and metastasis [1,26]. Thus, strategies interfering with the signaling pathways activating NFκB have become major targets for anti-cancer interventions [27]. The negative feedback loop controlling NFκB activity is critically regulated by the phosphorylation status of the upstream kinase IKKβ. Phosphorylation of Ser 177/181 is a prerequisite for initial phosphorylation and degradation of IκBα. *Vice versa*, dephosphorylation of these IKKβ serine residues is required to prevent phosphorylation of resynthesized IκBα being a prerequisite for NFκB termination [6]. Concerning the molecular mechanism underlying UVB-induced abrogation of the negative feedback loop, we have recently discovered Ser-Thr-phosphatase PP2A to be crucially involved in tuning the phosphorylation status of IKKβ. Impeding IκBα re-appearance upon co-stimulation with UVB was linked to UVB-induced inhibition of PP2Ac, causing chronic IKKβ phosphorylation followed by downstream phosphorylation and degradation of resynthesized IκBα [10]. Understanding the general PP2Ac/IKKβ cross talk at the IKK complex, the mode of interference of UVB with PP2Ac activity and the chronology of events leading to full abrogation of the negative feedback loop is of high importance under therapeutic aspects.

Conflicting data about the contribution of PP2A in modulating NFκB activity exist, while most of the reports connect inhibition of PP2A to NFκB activation [10,28-32]. Less evidence exists suggesting IKK-PP2A complex formation to be a prerequisite for TNF-induced phosphorylation of IKKβ and degradation of IκBα [33]. Developing a new reduced mathematical model strictly relying on experimental data, we could confirm the critical role of PP2A in antagonizing IKKβ phosphorylation and consequently NFκB activity. By this means we were able to





**Figure 5**

**Model parameters are very well identifiable and suggest indirect deactivation of PP2Ac by UVB. (A)** The histograms show the parameter values of the best 10% out of 4000 fits. The initial parameter values for these fits were obtained by randomly varying the parameter values of the reference scenario (Table 1) by up to 4 orders of magnitude, as described in the *Methods* section. **(B)** The model rejects the hypothesis of immediate UVB induced PP2Ac deactivation. Assuming  $kdp = 0$  in case of UVB stimulation, the experimental data cannot be reproduced ( $\chi^2 = 72.05 + 37.78 = 109.83$ ).

**Table 2: 95%-confidence intervals of the parameters in the reference scenario**

Variable	95%-confidence interval	Unit
ka	[5.0, 8.5]	( $\mu\text{M}\cdot\text{s}$ ) <sup>-1</sup>
ki	[0.0025, 0.0042]	s <sup>-1</sup>
kp	[0.095, 0.095]	s <sup>-1</sup>
kdp	[0.00060, 0.0011]	s <sup>-1</sup>
kuv	[0.00016, 0.00032]	s <sup>-1</sup>
IKKscale	[0.78, 1.2]	-

Confidence intervals were obtained by fitting to perturbed experimental data and determining the 2.5% and 97.5% quantiles of the resulting parameter sets, as described in the *Methods* section.

unravel the most evident activation status of PP2A at the IKK complex and to predict a mechanism underlying UVB-induced PP2Ac inactivation:

In unstimulated cells PP2A is most likely associated with the IKK complex in a constitutively active fashion, where it presumably controls dephosphorylation of randomly activated IKK $\beta$ . Accordingly, we propose the following model of PP2A function at the IKK complex: In case of IL-1 mediated IL-1 receptor activation, the initial signal input causing IKK $\beta$  phosphorylation overrules constitutive PP2A activity, resulting in a net shift towards increase in phosphorylated, i.e. active, IKK $\beta$  species, which reach a peak after approximately 15 min. At this time point, I $\kappa$ B $\alpha$  degradation is completed, but the exogenous IL-1 signal is already close to terminated due to rapid IL-1R internalization. Continuing PP2A activity thus results in a reversion of the IKK $\beta$  status towards an unphosphorylated, inactive species, which subsequently allows accumulation of resynthesized I $\kappa$ B $\alpha$ . In case of PP2Ac inhibition by co-stimulation with UVB, however, the dephosphorylation of IKK $\beta$  is strongly impaired, resulting in persistent degradation of newly synthesized I $\kappa$ B $\alpha$ , thereby causing abrogation of the negative feedback loop. Persistent nuclear NF $\kappa$ B activity then promotes pro-apoptotic instead of anti-apoptotic responses under these specific conditions [10].

A constitutive PP2A activity is also consistent with the elusive IKK inactivation mechanism in the model of [18] and may present a promising candidate for the yet unknown fast IKK inactivation mechanism following TNF $\alpha$  stimulation. We could substantially improve our previous modeling approach for IL-1 induced IKK phosphorylation [19] and now present a validated model with well identifiable parameters that incorporates recent findings about the IKK deactivation process. It is independent of the downstream processes and only contains processes strictly necessary to describe the observed dynamics.


The present model structure contains several simplifying assumptions. Particularly, neither hyperphosphorylation

nor constitutive protein synthesis and degradation are included, in contrast to other models, e.g. [21]. As shown in detail in Additional file 1, V, these simplifications are consistent with biological considerations and further supported by the fact that a model including these extensions does not perform better than the original model. This finding does not refute the different model structure chosen by Lipniacki et al. [21] but rather indicates that the mechanism of IKK $\beta$  deactivation following IL-1 stimulation may differ from that following TNF $\alpha$  stimulation.

Besides the validated predictions concerning the fast receptor kinetics, the model predicted that deactivation of PP2A located at the IKK following UVB radiation does not occur directly through UVB modifications of PP2A. This prediction is consistent with data from Barisic et al. [10], where total cellular PP2Ac activity is decreased, but still discernable following 2 h of UVB radiation. Although direct inactivation by UVB-mediated destruction of aromatic amino acids in the catalytic centre of Tyr-phosphatases has been reported [34,35] this does not seem to be the case for Ser/Thr-phosphatase PP2A. Accordingly, indirect deactivation of PP2A by UVB is most likely facilitated by other mediators yet to be identified.

## Conclusion

We developed a model of IKK $\beta$  phosphorylation with well identifiable parameters that is independent of the downstream processes. This model can be used as a reliable building block for the input of NF $\kappa$ B models investigating the mechanisms associated with the persistent activation of NF $\kappa$ B, which results in pro-apoptotic behavior when combined with UVB and other DNA damaging agents [9,10,36,37]. In contrast to the vast majority of mathematical models for the NF $\kappa$ B signaling pathway, the present model considers IKK phosphorylation independently of I $\kappa$ B $\alpha$  and NF $\kappa$ B. This decouples IKK phosphorylation kinetics from I $\kappa$ B $\alpha$  kinetics and allows for a considerable reduction of the system order. The obtained small model allows for reliable determination of biological parameters such as IKK $\beta$  dephosphorylation half-life or half-life of UVB induced PP2Ac deactivation, which are often difficult to obtain experimentally. The simplifying assumptions on which the model is based are supported by biological and model-based reasoning as well as by the good fits to the experimental data and model validation, thus offering a comprehensive simplification potential for future modelling of NF $\kappa$ B signalling. Furthermore, model expansions are very easy to implement, due to the modular model structure which links different modules by signal flows only. These expansions could involve modeling of the omitted proteins in the signaling cascade such as IRAK or TRAF6 [38], or the system behavior for variable UVB doses. For long term studies, constitutive protein synthesis and degradation could be taken into account. Model expansions might also be required for low IL-1



**Figure 6**  
**UVB does not alter IKK $\beta$  phosphorylation via delay of IL-1 receptor internalization.** (A) Cells were left untreated or stimulated with IL-1 (10 ng/ml) alone or in combination with UVB (300 J/m<sup>2</sup>) for the indicated time points. Subsequently, IL-1 receptor expression was analyzed by flow cytometry using an IL-1 receptor specific antibody compared to an isotype control of the secondary antibody (FITC). The mean fluorescence intensity (MnX) of three independently performed experiments of this control was set as 1. Receptor expression levels were determined respectively and the MnX of three independently performed experiments compared to FITC control is presented. Consequently, an MnX of 1 in the experiments represents a completely internalized or degraded receptor. (B) The hypothesis of receptor internalization leads to a considerably inferior fit quality ( $\chi^2 = 24.77 + 25.35 = 50.12$ ). The model largely diverges from the experimental data for the 30 min value following IL-1 stimulation and systematically underestimates the last 5 data points following IL-1 + UVB stimulation.

stimulations where a variable IL-1 level or effects in the signaling cascade could play a more prominent role. Combining experimental and modeling approaches sheds new light on the dynamics of IKK $\beta$  phosphorylation and the understanding of the negative feedback loop regulation of NF $\kappa$ B. With respect to tumor maintenance and progression resulting from constitutive NF $\kappa$ B activation [39,40], the specific cellular activation status of PP2A should be considered by support of mathematical models, and may consequently help to elucidate alternative therapeutic targets to fight individual cancers.

## Methods

### Cells and reagents

The human epithelial carcinoma cell line KB (ATCC) was cultured in RPMI 1640, 10% FCS. Subconfluent cells were stimulated in colorless medium with 2% FCS. UVB irradiation (300 J/m<sup>2</sup>) was performed with TL12 fluorescent bulbs (290–320 nm, Philips). Recombinant human IL-1 $\beta$  (R&D Systems) was applied at 10 ng/ml and 0.5 ng/ml, respectively, as indicated. PP2Ac knock down was facilitated by transfecting  $6 \times 10^5$  cells with 50 pmol siRNA: 5'-GAGGUUCGAUGUCCAGUUA-3' (MWG) using Lipofectamine 2000 (Invitrogen) 48 h prior to stimulation. Scrambled siRNA 5'-UAGAAUUAUCCUCAACAG-3' served as negative control.

### Western-blot analysis

Cells were harvested via the hot lysis method. Briefly at the indicated time points supernatants were aspirated and adherent cells lysed by addition of 100  $\mu$ l of hot (95°C) laemmli buffer followed by sonication and incubation at 95°C for further 10 min. After centrifugation, supernatants were collected and 15  $\mu$ l of each protein samples subjected to 10–12% SDS-PAGE, blotted onto nitrocellulose membranes and incubated with antibodies directed against pSer177/181-IKK $\beta$ , I $\kappa$ B $\alpha$  and PP2Ac (16A6, L35A5, 2038; Cell Signaling) respectively. Equal loading was monitored by reprobing membranes with an antibody against  $\alpha$ -tubulin (DM1A, Neomarkers) and HRP conjugated secondary antibodies (Amersham, Buckinghamshire, UK). Bands were visualized applying chemiluminescence SuperSignal<sup>®</sup> detection system (PIERCE). Relative IKK phosphorylation was quantified densitometrically from Western Blots and normalized against  $\alpha$ -tubulin levels using Image Quant<sup>™</sup> software. An initial phosphorylation level of 0 for unstimulated IKK was assumed. Time series were scaled in a way that their mean equaled one, subsequently pooled, and finally scaled in a way that the mean maximal value of both pooled time series equaled one.

### FACS analysis

To monitor levels of membrane bound IL-1R, FACS analysis was performed utilizing 0.5  $\mu$ g of an anti IL-1R mouse IgG (551388, Becton Dickinson) in 100  $\mu$ l PBS/1% BSA per  $5 \times 10^5$  cells and a goat anti mouse IgG conjugated to FITC (F9137, Sigma). Cells were analyzed in an EPICS<sup>®</sup> XL-MCL flow cytometer (Coulter, Miami, USA). Excitation wavelength used for FITC was 488 nm. The emitted green fluorescence ( $\lambda_{\max}$  520 nm) was detected using (FL-1) band pass filter. 20 000 cells were analysed for each sample. Data analysis was performed using the WIN/MDI 2.8 software.

### Phosphatase assay

Cells were lysed as described above. Endogenous PP2Ac was immunoprecipitated using a specific antibody (PC

12–301, Upstate) and A/G-plus agarose (Santa Cruz) overnight. Immunoprecipitated PP2Ac was diluted in 74  $\mu$ l phosphatase assay buffer (50 mM Tris/HCl, pH 7.0; 100  $\mu$ M CaCl<sub>2</sub>) and incubated with 6  $\mu$ l threonine phosphopeptide (final conc. 75  $\mu$ M; Biomol) for 5 min at 30°C. 20  $\mu$ l malachite green solution (Bio Assay Systems) was added and absorption measured at different time points at 650 nm. Phosphatase activity of un-irradiated cells was determined to be 100%. As an assay standard a serial dilution of 40  $\mu$ M phosphate (Bio Assay Systems) was used. Equal amounts of immunoprecipitated PP2Ac were monitored by Western-blot analysis following the phosphatase assay compared to cell lysate with a specific anti PP2Ac antibody (2038, Cell Signaling).

### Model Analysis

The MATLAB (The MathWorks) based software tool box PottersWheel 1.6 [41] was used for the solution, optimization and analysis of the ordinary differential equation system. The  $\chi^2$  value was chosen as objective function, with

$$\chi^2(\theta) = \sum_{i=1}^N \frac{(y_i - \gamma(t_i; \theta))^2}{\sigma_i^2}$$

where  $y_i$  is data point  $i$  with standard deviation  $\sigma_i$  and  $\gamma(t_i; \theta)$  is the model value at time point  $i$  for the parameter vector  $\theta$ . Initial parameter values prior to the first optimization were arbitrarily chosen as 0.05 for all parameters. Minimization was performed using the FitBoost routine, which combines a trust region and a simulated annealing approach. Additionally, 4000 fits with the trust region approach were performed, each starting from the parameter values of the currently best fit randomly disturbed by up to 4 orders of magnitude (pwF3 routine), thus covering a range of 8 orders of magnitude.

In order to assess the reliability of the obtained best fit parameters, we investigated whether they can be uniquely determined for the given experimental data (identifiability analysis) and how perturbations of the experimental data within the measuring accuracy affect the parameter estimation (confidence intervals).

Identifiability analysis was performed by conducting 4000 independent fits with the trust region method, each starting from the parameter values of the best fit randomly disturbed by up to 4 orders of magnitude (pwF2 routine). The best 10% of the fits were selected for analysis. For estimation of the confidence intervals, 500 new data sets were generated by adding an  $N(0, \sigma_i^2)$  distributed error term to each data point of the original data, where  $\sigma_i$  is the experimentally determined standard deviation at time point  $i$ .

Separate fitting was performed for each data set, using the FitBoost routine. Additionally 200 fits were performed with the pwF3 routine with random perturbations of up to 2 orders of magnitude, in order to reduce the computational effort. The 2.5% and 97.5% quantiles of the resulting parameter sets were determined.

### Authors' contributions

JW performed the mathematical modelling and analysis, supervised by TS. SB performed the biochemical experiments and was supported by ES. The present study emerged from previous studies of DKs lab. She conceived and supervised the experimental part of the study. JW and DK drafted the manuscript, revised then by OS and TS. DK, FA and TS developed the general guidelines of the project. All authors read and approved the final manuscript.

### Additional material

#### Additional file 1

*Supplementary information about the modelling procedure. Includes a more detailed description of several aspects of the modelling procedure.*

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1752-0509-3-71-S1.pdf>]

#### Additional file 2

*Simulation results of the reference model with different parameterization. The fit is slightly worse but visually more satisfactory than the reference scenario.*

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1752-0509-3-71-S2.pdf>]

#### Additional file 3

*Simulation results for the alternative model with delayed PP2A activation. Shows the fit and describes the model equations of the alternative model.*

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1752-0509-3-71-S3.pdf>]

#### Additional file 4

*Representative Western Blot Analysis. Representative Western Blot of PP2Ac-dependent IKK $\beta$  phosphorylation*

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1752-0509-3-71-S4.pdf>]

#### Additional file 5

*Simulation results for IL-1 receptor internalisation. Shows the amount of total IL-1 receptor (ILR + ILRc) in the reference scenario.*

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1752-0509-3-71-S5.pdf>]

## Acknowledgements

This work was supported by grants from the Deutsche Forschungsgesellschaft (DFGKU 1981/I-1). We thank Markus Koschorreck and Klaus Pfizenmaier for inspiring discussions and critically reading the manuscript.

## References

- Aggarwal BB: **Nuclear factor-kappaB: the enemy within.** *Cancer Cell* 2004, **6**:203-208.
- Cortes SM, Rodriguez FV, Sanchez PI, Perona R: **The role of the NF-kappaB signalling pathway in cancer.** *Clin Transl Oncol* 2008, **10**:143-147.
- Maeda S, Omata M: **Inflammation and cancer: role of nuclear factor-kappaB activation.** *Cancer Sci* 2008, **99**:836-842.
- Naugler WE, Karin M: **NF-kappaB and cancer-identifying targets and mechanisms.** *Curr Opin Genet Dev* 2008, **18**:19-26.
- Karin M, Yamamoto Y, Wang QM: **The IKK NF-kappa B system: a treasure trove for drug development.** *Nat Rev Drug Discov* 2004, **3**:17-26.
- Delhase M, Hayakawa M, Chen Y, Karin M: **Positive and negative regulation of I kappa B kinase activity through IKKbeta subunit phosphorylation.** *Science* 1999, **284**:309-313.
- Kothny-Wilkes G, Kulms D, Poppelmann B, Luger TA, Kubin M, Schwarz T: **Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand.** *J Biol Chem* 1998, **273**:29247-29253.
- Kothny-Wilkes G, Kulms D, Luger TA, Kubin M, Schwarz T: **Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand- and CD95-induced apoptosis but not from ultraviolet radiation-induced apoptosis.** *J Biol Chem* 1999, **274**:28916-28921.
- Pöppelmann B, Klimmek K, Strozzyk E, Voss R, Schwarz T, Kulms D: **NF-kappaB-dependent down-regulation of tumor necrosis factor receptor-associated proteins contributes to interleukin-1 mediated enhancement of ultraviolet B-induced apoptosis.** *J Biol Chem* 2005, **280**:15635-15643.
- Barisic S, Strozzyk E, Peters N, Walczak H, Kulms D: **Identification of PP2A as a crucial regulator of the NF-kappaB feedback loop: its inhibition by UVB turns NF-kappaB into a pro-apoptotic factor.** *Cell Death Differ* 2008, **15**:1681-1690.
- Scott ML, Fujita T, Liou HC, Nolan GP, Baltimore D: **The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms.** *Genes Dev* 1993, **7**:1266-1276.
- Cheong R, Hoffmann A, Levchenko A: **Understanding NF-kappaB signaling via mathematical modeling.** *Mol Syst Biol* 2008, **4**:192.
- Hoffmann A, Levchenko A, Scott ML, Baltimore D: **The I kappa B-NF-kappaB signaling module: temporal control and selective gene activation.** *Science* 2002, **298**:1241-1245.
- Hengl S, Kreutz C, Timmer J, Maiwald T: **Data-based identifiability analysis of non-linear dynamical models.** *Bioinformatics* 2007, **23**:2612-2618.
- Cho KH, Shin SY, Lee HW, Wolkenhauer O: **Investigations into the analysis and modeling of the TNF alpha-mediated NF-kappa B-signaling pathway.** *Genome Res* 2003, **13**:2413-2422.
- Park SG, Lee T, Kang HY, Park K, Cho KH, Jung G: **The influence of the signal dynamics of activated form of IKK on NF-kappaB and anti-apoptotic gene expressions: a systems biology approach.** *FEBS Lett* 2006, **580**:822-830.
- Werner SL, Barken D, Hoffmann A: **Stimulus specificity of gene expression programs determined by temporal control of IKK activity.** *Science* 2005, **309**:1857-1861.
- Cheong R, Bergmann A, Werner SL, Regal J, Hoffmann A, Levchenko A: **Transient I kappa B kinase activity mediates temporal NF-kappaB dynamics in response to a wide range of tumor necrosis factor-alpha doses.** *J Biol Chem* 2006, **281**:2945-2950.
- Witt J, Husser S, Kulms D, Barisic S, Sawodny O, Sauter T: **Modeling of IL-1 induced NF-kappaB signaling and analysis of ional UVB influence.** *SICE 2007 Annual Conference* 2007, **1**:1353-1358.
- Heinrich R, Schuster S: *The regulation of cellular systems* 1st edition. New York: Chapman & Hall; 1996.
- Lipniacki T, Paszek P, Brasier AR, Luxon B, Kimmel M: **Mathematical model of NF-kappaB regulatory module.** *J Theor Biol* 2004, **228**:195-215.
- Krikos A, Laherty CD, Dixit VM: **Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements.** *J Biol Chem* 1992, **267**:17971-17976.
- Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, Ma A: **Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice.** *Science* 2000, **289**:2350-2354.
- Qwarnstrom EE, Page RC, Gillis S, Dower SK: **Binding, internalization, and intracellular localization of interleukin-1 beta in human diploid fibroblasts.** *J Biol Chem* 1988, **263**:8261-8269.
- Bonizzi G, Piette J, Merville MP, Bours V: **Distinct signal transduction pathways mediate nuclear factor-kappaB induction by IL-1beta in epithelial and lymphoid cells.** *J Immunol* 1997, **159**:5264-5272.
- Luque I, Gelinas C: **Rel/NF-kappa B and I kappa B factors in oncogenesis.** *Semin Cancer Biol* 1997, **8**:103-111.
- Lin A, Karin M: **NF-kappaB in cancer: a marked target.** *Semin Cancer Biol* 2003, **13**:107-114.
- Hong S, Wang LC, Gao X, Kuo YL, Liu B, Merling R, Kung HJ, Shih HM, Giam CZ: **Heptad repeats regulate protein phosphatase 2a recruitment to I-kappaB kinase gamma/NF-kappaB essential modulator and are targeted by human T-lymphotropic virus type I tax.** *J Biol Chem* 2007, **282**:12119-12126.
- Palkowitsch L, Leidner J, Ghosh S, Marienfeld RB: **Phosphorylation of serine 68 in the I kappa B kinase (IKK)-binding domain of NEMO interferes with the structure of the IKK complex and tumor necrosis factor-alpha-induced NF-kappaB activity.** *J Biol Chem* 2008, **283**:76-86.
- Sun SC, Maggirwar SB, Harhaj E: **Activation of NF-kappa B by phosphatase inhibitors involves the phosphorylation of I kappa B alpha at phosphatase 2A-sensitive sites.** *J Biol Chem* 1995, **270**:18347-18351.
- Sung SJ, Walters JA: **Stimulation of interleukin-1 alpha and interleukin-1 beta production in human monocytes by protein phosphatase 1 and 2A inhibitors.** *J Biol Chem* 1993, **268**:5802-5809.
- Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA: **Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli.** *EMBO J* 1995, **14**:2876-2883.
- Kray AE, Carter RS, Pennington KN, Gomez RJ, Sanders LE, Llanes JM, Khan WN, Ballard DW, Wadzinski BE: **Positive regulation of I kappa B kinase signaling by protein serine/threonine phosphatase 2A.** *J Biol Chem* 2005, **280**:35974-35982.
- Knebel A, Rahmsdorf HJ, Ullrich A, Herrlich P: **Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents.** *EMBO J* 1996, **15**:5314-5325.
- van Montfort RL, Congreve M, Tisi D, Carr R, Jhoti H: **Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B.** *Nature* 2003, **423**:773-777.
- Campbell KJ, Rocha S, Perkins ND: **Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B.** *Mol Cell* 2004, **13**:853-865.
- Strozzyk E, Poppelmann B, Schwarz T, Kulms D: **Differential effects of NF-kappaB on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome.** *Oncogene* 2006, **25**:6239-6251.
- O'Neill LA, Greene C: **Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants.** *J Leukoc Biol* 1998, **63**:650-657.
- Ahn KS, Sethi G, Aggarwal BB: **Nuclear factor-kappa B: from clone to clinic.** *Curr Mol Med* 2007, **7**:619-637.
- Sethi G, Sung B, Aggarwal BB: **Nuclear factor-kappaB activation: from bench to bedside.** *Exp Biol Med (Maywood)* 2008, **233**:21-31.
- Maiwald T, Timmer J: **Dynamical modeling and multi-experiment fitting with PottersWheel.** *Bioinformatics* 2008, **24**:2037-2043.